Clinical Trials
12
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 440
- Registration Number
- NCT06953089
- Locations
- 🇺🇸
Research Site USA04-0, New York, New York, United States
🇺🇸Research Site USA03-0, Charleston, South Carolina, United States
🇦🇺Research Site AUS02-0, North Ryde BC, New South Wales, Australia
A Phase 1 Study of DB-2304 in Healthy Adults and SLE Participants
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT06625671
- Locations
- 🇦🇺
Site AUS01-0, Melbourne, Victoria, Australia
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT06554795
- Locations
- 🇺🇸
Site USA08-0, Newport Beach, California, United States
🇺🇸Site USA06-0, Washington, D.C., District of Columbia, United States
🇺🇸Site USA02, Florida City, Florida, United States
A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 224
- Registration Number
- NCT06265428
- Locations
- 🇨🇳
015, Bengbu, Anhui, China
🇨🇳016, Hefei, Anhui, China
🇨🇳029, Hefei, Anhui, China
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 532
- Registration Number
- NCT06018337
- Locations
- 🇺🇸
Research Site 1141-0, Tucson, Arizona, United States
🇺🇸Research Site 1114-0, Fullerton, California, United States
🇺🇸Research Site 1107-0, Los Angeles, California, United States
- Prev
- 1
- 2
- Next